Valneva SE Logo

Valneva SE

Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.

VLA | PA

Overview

Corporate Details

ISIN(s):
AT0000A10B99 (+3 more)
LEI:
969500DIVIP5VKNW4948
Country:
France
Address:
6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company leverages its expertise to manage a portfolio of commercialized vaccines, including a single-shot vaccine for chikungunya, and to advance a clinical pipeline of candidates. Key development programs target diseases such as Lyme disease, Shigella, and Zika.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-09 15:59
Major Shareholding Notification
Franchissement de seuil
French 205.6 KB
2025-10-06 17:35
Capital/Financing Update
Valneva consolide sa position de trésorerie en refinançant sa dette auprès de P…
French 202.1 KB
2025-10-06 17:35
Capital/Financing Update
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advis…
English 212.7 KB
2025-08-07 07:17
Regulatory News Service
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du v…
French 218.7 KB
2025-08-07 07:17
Regulatory News Service
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccin…
English 222.5 KB
2025-07-11 17:35
Regulatory News Service
Valneva annonce la levée de la restriction temporaire de l'Agence européenne de…
French 165.8 KB
2025-07-11 17:35
Regulatory News Service
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction …
English 208.0 KB
2025-06-25 17:45
Post-Annual General Meeting Information
Valneva annonce l’approbation des résolutions présentées à son Assemblée Généra…
French 145.4 KB
2025-06-25 17:45
Post-Annual General Meeting Information
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY…
English 119.4 KB
2025-06-05 17:45
Earnings Release
Valneva annonce des résultats positifs de Phase 2 à six mois sur la persistance…
French 236.5 KB
2025-06-05 17:45
Earnings Release
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Resu…
English 178.3 KB
2025-06-05 07:30
Declaration of Voting Results & Voting Rights Announcements
[Valneva SE] Déclaration d’actions et de droits de vote - mai 2025
French 160.2 KB
2025-06-05 07:30
Declaration of Voting Results & Voting Rights Announcements
[Valneva SE] Declaration of shares and voting rights - May 2025
English 170.0 KB
2025-06-04 07:00
Pre-Annual General Meeting Information
Valneva annonce la mise à disposition des documents préparatoires à son Assembl…
French 115.0 KB
2025-06-04 07:00
Pre-Annual General Meeting Information
Valneva Announces Availability of Documentation for its Combined Shareholder Me…
English 122.8 KB

Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Valneva SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-03-18 N/A Other Buy 44,222 N/A
2024-01-03 N/A Other Other 34,802 N/A
2023-06-20 N/A Other Sell 192,547 1,406,228.50 EUR
2023-06-19 N/A Other Sell 30,661 209,629.26 EUR
2023-06-16 N/A Other Sell 85,589 582,493.06 EUR
2023-06-15 N/A Other Sell 28,179 189,503.78 EUR
2023-06-14 N/A Other Sell 228,951 1,519,914.11 EUR
2023-06-13 N/A Other Sell 29,401 187,922.37 EUR
2023-06-12 N/A Other Sell 117,854 733,782.57 EUR
2023-05-10 N/A Other Buy 87,523 N/A

Peer Companies

Company Country Ticker View
Global manufacturer of carbapenem antibiotic APIs for regulated markets.
South Korea 106190
HIKMA Pharmaceuticals PLC Logo
Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.
United Kingdom HIK
HISAMITSU PHARMACEUTICAL CO.,INC. Logo
A global leader in transdermal drug delivery systems for OTC and prescription pain relief.
Japan 4530
HLB Genex, Inc. Logo
Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.
South Korea 187420
HLB INC. Logo
A diversified group in pharma, shipbuilding, life sciences, and professional advisory services.
South Korea 028300
HLB Life Science CO.,LTD. Logo
Develops anti-cancer drugs and distributes IVD medical devices and lab supplies internationally.
South Korea 067630
HLB PANAGENE Co., LTD. Logo
A global leader in PNA technology for cancer diagnostics and precision medicine.
South Korea 046210
HLB Pep Co., Ltd. Logo
Develops and produces GMP peptides, APIs, and custom synthesis for the biopharma industry.
South Korea 196300
HLB PHARMACEUTICAL CO., LTD. Logo
Researches cancer drugs and offers pharmaceutical CMO and manufacturing services.
South Korea 047920
HLB SCIENCE Inc. Logo
Develops innovative therapeutics and diagnostics for infectious and neurodegenerative diseases.
South Korea 343090

Talk to a Data Expert

Have a question? We'll get back to you promptly.